Clinical Features of Patients with COVID-19 Recurrence During Hospitalization in the Omicron Variant Surge
Masafumi Seki,Chie Kubosawa,Makoto Ono,Fumitaka Kamoshita,Atsuko Shimizu,Kotaro Mitsutake
DOI: https://doi.org/10.2147/idr.s485976
2024-11-13
Infection and Drug Resistance
Abstract:Masafumi Seki, Chie Kubosawa, Makoto Ono, Fumitaka Kamoshita, Atsuko Shimizu, Kotaro Mitsutake Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan Correspondence: Masafumi Seki, Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Yamane 1397-1, Hidaka City, Saitama, 350-1298, Japan, Tel +81-42-984-4392, Fax: +81-42-984-0280, Email Background: Repeat positive results for SARS-CoV-2 by antigen detection test/RT-PCR in recovered COVID-19 patients were not very rare even when omicron variants became dominant, but the clinical features of patients with recurrent COVID-19 during hospitalization are still unclear. Methods: The clinical characteristics of patients with recurrent COVID-19 during hospitalization were retrospectively investigated from January 2023 to December 2023. Results: Recurrence of COVID-19 was found in 7 of 275 (2.5%) patients during hospitalization. Their mean age was 80.3 (74– 89) years, and 4 of 7 (57.1%) patients were hospitalized on the hematology ward with B cell/non-Hodgkin lymphoma. These 4 lymphoma patients had been vaccinated, but the other 3 patients hospitalized on the emergency ward and the neurology ward had not been vaccinated. Of the 7 patients, 6 (85.7%) were initially treated with remdesivir (RDV), but only 3 patients were re-treated with RDV, and the other 4 patients were successfully re-treated with oral 3C-like protease inhibitors, such as ensitrelvir (ESV) and nirmatrelvir/ritonavir (N/R). Conclusion: These data suggest that COVID-19 recurrence was found in patients with hematological disorders, such as lymphoma, and/or patients with no vaccination history. However, these patients were treated successfully by re-administration of anti-SARS-CoV-2 agents, including ESV and N/R. Keywords: SARS-CoV-2, remdesivir, nirmatrelvir/ritonavir, ensitrelvir, rituximab, Anti-CD20+ B cell depletion COVID-19 has had an enormous impact on societies worldwide, and SARS-CoV-2 is currently well treated using antiviral agents, such as remdesivir (RDV: Gilead, Foster City, CA, USA), which has been recommended as the first-choice treatment for moderate and hospitalized COVID-19 patients. 1,2 RDV can improve the patient's condition along with reduction of viral antigen titers, but in some patients, the virus is not eliminated completely, and there is recurrence of COVID-19 even though the patients remain hospitalized and quarantined. 3,4 In this study, we investigated the recurrent patients and found that there were 7 recurrent cases of COVID-19 during hospitalization of a total of 275 (7/275= 2.5%) COVID-19 patients admitted to our hospital from January 2023 to December 2023 (Table 1). This case study was approved by the Institutional Review Board of Saitama Medical University International Medical Center (#2022-032) on July 6, 2022, and registered as UMIN000047691. All patients participating in this study provided written, informed consent as part of the comprehensive consent obtained at admission to have any accompanying images and their case details published. The patients were provided the means to opt out of these clinical studies in particular. This study adhered to the Declaration of Helsinki. Table 1 Characteristics of Patients with COVID-19 Recurrence During Hospitalization In addition, the definition of the recurrence of COVID-19 was matched with the following both 1) and 2) although the patients continued the isolated hospitalization and had been already asymptomatic and negative of SARS-Cov-2 antigens/Ct value of PCR upper than 35 after the first the anti-COVID-19 therapy: 1) the patients who had the fever and/or respiratory symptoms, including 8 investigated symptoms (cough, chills, dyspnea, fatigue, fever, nasal discharge, sore throat, and sputum) again, and 2) SARS-Cov-2 antigens became positive andor/Ct value of PCR became 35 and the less again. The mean age of the 7 patients was 80.3 (74–89) years, and the male-to-female ratio was 4:3, with 57.1% males. In detail, 4 of the 7 (57.1%) patients were hospitalized on the hematology ward due to B cell/non-Hodgkin lymphoma. The 4 lymphoma patients had been vaccinated at least once by pfizer-BioNTech COVID-19 vaccines (Comirnaty, Pfizer Inc. New York, NY, USA) or Moderna COVID-19 vaccines (Spikevax, Moderna Inc. Cambridge, MA, USA), but the 3 other patients who had been hospitalized on the emergency ward and the neurology wards had not been vaccinated. Of the 7 patients, 6 (85.7%) were initially treated with RDV 200 mg drip infusion, followed by 100 mg per day for 5 days, and the other one patient did not receive antiviral treatment. In 5 of the 7 patients, the SARS-CoV-2 antig -Abstract Truncated-
pharmacology & pharmacy,infectious diseases